Insights - Last week we introduced a new look for PropThink.com and launched a more affordable option for PropThink readers interested in exploring our Premium content. Not to worry, we’ll still … Continue Reading
Read nowInsights - Get Your First Month of PropThink Premium Half-Off Check out the Revamped PropThink.com Two Products Mean the Same Impactful Content at a Lower Price-Point We’re pleased to … Continue Reading
Read nowMost Popular - Questcor Pharmaceuticals (QCOR) reported stellar earnings this week, topping analyst’s expectations for Acthar sales of $199.7 million by more than 15%: revenues in the quarter … Continue Reading
Read nowLong Ideas - After a negative vote from the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and repeat signals that the regulatory agency was taking a hardline … Continue Reading
Read nowRecap - Medivation (MDVN) announced on Tuesday morning that the Phase III PREVAIL study, testing Xtandi (enzalutamide) in chemotherapy-naive patients with advanced prostate cancer, was stopped early … Continue Reading
Read nowLong Ideas - ResMed (RMD) is suing a new and low-cost competitor in the Continues Positive Airway Pressure market. The target, 3B Medical, isn’t taking the litigation lying … Continue Reading
Read nowLong Ideas - This week was dominated by a number of binary events (which we outlined on Monday), two of which played out against us; Dr. Chaudhry expected that … Continue Reading
Read now